News
Apogee buy delivers eczema trial win for AbbVie
AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
News
Lilly fleshes out triple G data in diabetes and obesity
Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.
News
uniQure falls on long-term Huntington's gene therapy data
uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.
News
Novo turns to Hengrui for another oral obesity drug
Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
News
Mirum puts Hepcludex in its sights with hep D readout
Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
